<DOC>
	<DOCNO>NCT00974675</DOCNO>
	<brief_summary>This study include subject asthma participate one three group randomly assign group receive drug study ( CAT-354 ) placebo .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability Multiple Doses Multi-Level Drug Subjects With Moderate Asthma</brief_title>
	<detailed_description>This study randomise , double-blind , placebo control study . Following confirmation eligibility , subject moderate asthma recruit sequentially one three dose group randomly assign within dose group either CAT-354 placebo . Doses assign treatment administer three occasion 28 day apart . Follow pharmacokinetic blood sample safety continue Day 147 post first dose ( 91 day post third dose ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Males infertile female Subjects asthma , well control inhale corticosteroid PRN short act B2 agonist therapy Unchanged dose inhale corticosteroid three month prior day 0 expect need change dose study FEV1 great equal 80 % predict screening ( baseline ) 1860 year GP diagnosis asthma 1 year 's min . duration ( respect Day 0 ) No significant abnormality clinical examination medical history ( exclude atopic skin sign , symptom history ) 12lead electrocardiogram clinical significant abnormality Clinical chemistry hematology urinalysis result within laboratory reference range deem clinically significant Investigator A negative screen drug abuse alcohol Body weight 50120kg Subjects age 1840 year inclusive must BMI 1832kg/m2 inclusive . Subjects age 4160 year must BMI 1830 kg/m2 , inclusive . Active concomitant disease , exception eczema Expected onset seasonal allergy administration last dose study medication History severe exacerbation within 3 year Day 0 Recorded use inhale short act B2 agonist medication symptom within 14 day Day 0 : More 6 dos per day one day More 3 dos per day 6 day Any medication : inhaled shortacting B2 agonist inhale corticosteroid topic eczema treatment ( exception fluorinated corticosteroid dermatological preparation permit hormone replacement therapy vitamin preparation/food supplement occasional use proton pump inhibitor , ranitidine , cimetidine , antacid overthecounter analgesic . Treatment within 6 month Day 0 follow : methylxanthines , inhale cromones , leukotriene modifier , anti IgE , anticholinergic , ketotifen , oral short act B2 agonist , longacting B2 agonist , oral injected corticosteroid Treatment atopic symptom , eczema , within 4 week Day 0 History medication might carryover effect study Previously receive monoclonal antibody , similar relate protein , might sensitise CAT354 Participation another study within three month start study 5 half live previously administer investigational medicinal product ( IMMP ) , whichever long Lower respiratory tract infection within four week Day14 Any acute illness two week Day 0 Current smoker , smoke previous year , smoke history great equal 10 pack year Considered investigator risk transmitting , blood , agent responsible infectious disease Blood donation ( 550mls ) previous 2 month Excessive intake alcohol ( 21 unit week female 28 unit week male ) The subject 's general practitioner suggest reason subject participate study The Investigator considers subject take part reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>